Tight junction proteins claudin-3 and claudin-4 control tumor growth and metastases

Neoplasia (United States)

Volumn 14, Issue 10, 2012, Pages 974-985

  Shang, Xiying ^a   Lin, Xinjian ^a   Alvarez, Edwin ^a   Manorek, Gerald ^a   Howell, Stephen B ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA CATENIN; CLAUDIN 3; CLAUDIN 4; GLYCOGEN SYNTHASE KINASE 3BETA; JUNCTIONAL ADHESION MOLECULE A; KI 67 ANTIGEN; OCCLUDIN; PROTEIN ZO1; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL ADHESION; CELL DEATH; CELL INTERACTION; CELL INVASION; CELL MEMBRANE PERMEABILITY; CELL MIGRATION; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; METASTASIS; MOUSE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR GROWTH;

EID: 84867756833     PISSN: 15228002     EISSN: 14765586     Source Type: Journal    
DOI: 10.1593/neo.12942     Document Type: Article

References (60)

1. Matter K and Balda MS (2003). Signalling to and from tight junctions. Nat Rev Mol Cell Biol 4, 225-236.
2. Schneeberger EE and Lynch RD (2004). The tight junction: a multifunctional complex. Am J Physiol Cell Physiol 286, C1213-C1228.
3. Langbein L, Pape UF, Grund C, Kuhn C, Praetzel S, Moll I, Moll R, and Franke WW (2003). Tight junction-related structures in the absence of a lumen: occludin, claudins and tight junction plaque proteins in densely packed cell formations of stratified epithelia and squamous cell carcinomas. Eur J Cell Biol 82, 385-400.
4. Itoh M and Bissell MJ (2003). The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis. J Mammary Gland Biol Neoplasia 8, 449-462.
5. Mullin JM (2004). Epithelial barriers, compartmentation, and cancer. Sci STKE 2004, pe2.
6. Hurd TW, Gao L, Roh MH, Macara IG, and Margolis B (2003). Direct interaction of two polarity complexes implicated in epithelial tight junction assembly. Nat Cell Biol 5, 137-142.
7. Kohler K and Zahraoui A (2005). Tight junction: a co-ordinator of cell signalling and membrane trafficking. Biol Cell 97, 659-665.
8. Thiery JP, Acloque H, Huang RY, and Nieto MA (2009). Epithelial-mesenchymal transitions in development and disease. Cell 139, 871-890.
9. Martin TA, Watkins G, Mansel RE, and Jiang WG (2004). Loss of tight junction plaque molecules in breast cancer tissues is associated with a poor prognosis in patients with breast cancer. Eur J Cancer 40, 2717-2725.
10. Choi YL, Kim J, Kwon MJ, Choi JS, Kim TJ, Bae DS, Koh SS, In YH, Park YW, Kim SH, et al. (2007). Expression profile of tight junction protein claudin 3 and claudin 4 in ovarian serous adenocarcinoma with prognostic correlation. Histol Histopathol 22, 1185-1195.
11. Hudson LG, Zeineldin R, and Stack MS (2008). Phenotypic plasticity of neoplastic ovarian epithelium: unique cadherin profiles in tumor progression. Clin Exp Metastasis 25, 643-655.
12. Lu KH, Patterson AP, Wang L, Marquez RT, Atkinson EN, Baggerly KA, Ramoth LR, Rosen DG, Liu J, Hellstrom I, et al. (2004). Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin Cancer Res 10, 3291-3300.
13. Hough CD, Sherman-Baust CA, Pizer ES, Montz FJ, Im DD, Rosenshein NB, Cho KR, Riggins GJ, and Morin PJ (2000). Large-scale serial analysis of gene expression reveals genes differentially expressed in ovarian cancer. Cancer Res 60, 6281-6287.
14. Rangel LB, Agarwal R, D'Souza T, Pizer ES, Alo PL, Lancaster WD, Gregoire L, Schwartz DR, Cho KR, and Morin PJ (2003). Tight junction proteins claudin-3 and claudin-4 are frequently overexpressed in ovarian cancer but not in ovarian cystadenomas. Clin Cancer Res 9, 2567-2575.
15. Santin AD, Zhan F, Bellone S, Palmieri M, Cane S, Bignotti E, Anfossi S, Gokden M, Dunn D, Roman JJ, et al. (2004). Gene expression profiles in primary ovarian serous papillary tumors and normal ovarian epithelium: identification of candidate molecular markers for ovarian cancer diagnosis and therapy. Int J Cancer 112, 14-25.
16. Heinzelmann-Schwarz VA, Gardiner-Garden M, Henshall SM, Scurry J, Scolyer RA, Davies MJ, Heinzelmann M, Kalish LH, Bali A, Kench JG, et al. (2004). Overexpression of the cell adhesion molecules DDR1, claudin 3, and Ep-CAM in metaplastic ovarian epithelium and ovarian cancer. Clin Cancer Res 10, 4427-4436.
17. Finch A, Shaw P, Rosen B, Murphy J, Narod SA, and Colgan TJ (2006). Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 100, 58-64.
18. Karst AM, Levanon K, and Drapkin R (2011). Modeling high-grade serous ovarian carcinogenesis from the fallopian tube. Proc Natl Acad Sci USA 108, 7547-7552.
19. Lee Y, Miron A, Drapkin R, Nucci MR, Medeiros F, Saleemuddin A, Garber J, Birch C, Mou H, Gordon RW, et al. (2007). A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol 211, 26-35.
20. Levanon K, Ng V, Piao HY, Zhang Y, Chang MC, Roh MH, Kindelberger DW, Hirsch MS, Crum CP, Marto JA, et al. (2010). Primary ex vivo cultures of human fallopian tube epithelium as a model for serous ovarian carcinogenesis. Oncogene 29, 1103-1113.
21. Yoshihara K, Tajima A, Yahata T, Kodama S, Fujiwara H, Suzuki M, Onishi Y, Hatae M, Sueyoshi K, Kudo Y, et al. (2010). Gene expression profile for predicting survival in advanced-stage serous ovarian cancer across two independent datasets. PLoS One 5, e9615.
22. Szasz AM, Nemeth Z, Gyorffy B, Micsinai M, Krenacs T, Baranyai Z, Harsanyi L, Kiss A, Schaff Z, Tokes AM, et al. (2011). Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer. Cancer Sci 102, 2248-2254.
23. Lee KW, Lee NK, Kim JH, Kang MS, Yoo HY, Kim HH, Um SH, and Kim SH (2012). Twist1 causes the transcriptional repression of claudin-4 with prognostic significance in esophageal cancer. Biochem Biophys Res Commun 423, 454-460.
24. Ersoz S, Mungan S, Cobanoglu U, Turgutalp H, and Ozoran Y (2011). Prognostic importance of claudin-1 and claudin-4 expression in colon carcinomas. Pathol Res Pract 207, 285-289.
25. Matsuoka T, Mitomi H, Fukui N, Kanazawa H, Saito T, Hayashi T, and Yao T (2011). Cluster analysis of claudin-1 and -4, E-cadherin, and β-catenin expression in colorectal cancers. J Surg Oncol 103, 674-686.
26. Tsutsumi K, Sato N, Tanabe R, Mizumoto K, Morimatsu K, Kayashima T, Fujita H, Ohuchida K, Ohtsuka T, Takahata S, et al. (2012). Claudin-4 expression predicts survival in pancreatic ductal adenocarcinoma. Ann Surg Oncol 19(suppl 3), 491-499.
27. Hewitt KJ, Agarwal R, and Morin PJ (2006). The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 6, 186.
28. Kominsky SL (2006). Claudins: emerging targets for cancer therapy. Expert Rev Mol Med 8, 1-11.
29. Ouban A and Ahmed AA (2010). Claudins in human cancer: a review. Histol Histopathol 25, 83-90.
30. Klymkowsky MW and Savagner P (2009). Epithelial-mesenchymal transition: a cancer researcher's conceptual friend and foe. Am J Pathol 174, 1588-1593.
31. Yilmaz M and Christofori G (2009). EMT, the cytoskeleton, and cancer cell invasion. Cancer Metastasis Rev 28, 15-33.
32. Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY, Brooks M, Reinhard F, Zhang CC, Shipitsin M, et al. (2008). The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133, 704-715.
33. Liu M, Casimiro MC, Wang C, Shirley LA, Jiao X, Katiyar S, Ju X, Li Z, Yu Z, Zhou J, et al. (2009). p21CIP1 attenuates Ras-and c-Myc-dependent breast tumor epithelial mesenchymal transition and cancer stem cell-like gene expression in vivo. Proc Natl Acad Sci USA 106, 19035-19039.
34. Reiman JM, Knutson KL, and Radisky DC (2010). Immune promotion of epithelial-mesenchymal transition and generation of breast cancer stem cells. Cancer Res 70, 3005-3008.
35. Wang L, Mezencev R, Bowen NJ, Matyunina LV, and McDonald JF (2011). Isolation and characterization of stem-like cells from a human ovarian cancer cell line. Mol Cell Biochem 363, 257-268.
36. Lau MT, Klausen C, and Leung PC (2011). E-cadherin inhibits tumor cell growth by suppressing PI3K/Akt signaling via β-catenin-Egr1-mediated PTEN expression. Oncogene 30, 2753-2766.
37. Yuecheng Y, Hongmei L, and Xiaoyan X (2006). Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis 23, 65-74.
38. Sawada K, Mitra AK, Radjabi AR, Bhaskar V, Kistner EO, Tretiakova M, Jagadeeswaran S, Montag A, Becker A, Kenny HA, et al. (2008). Loss of E-cadherin promotes ovarian cancer metastasis via alpha 5-integrin, which is a therapeutic target. Cancer Res 68, 2329-2339.
39. Morin PJ (2005). Claudin proteins in human cancer: promising new targets for diagnosis and therapy. Cancer Res 65, 9603-9606.
40. Singh AB, Sharma A, and Dhawan P (2010). Claudin family of proteins and cancer: an overview. J Oncol 2010, 541957.
41. Osanai M, Murata M, Nishikiori N, Chiba H, Kojima T, and Sawada N (2006). Epigenetic silencing of occludin promotes tumorigenic and metastatic properties of cancer cells via modulations of unique sets of apoptosis-associated genes. Cancer Res 66, 9125-9133.
42. Naik MU, Naik TU, Suckow AT, Duncan MK, and Naik UP (2008). Attenuation of junctional adhesion molecule-A is a contributing factor for breast cancer cell invasion. Cancer Res 68, 2194-2203.
43. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, Fridlyand J, Sahin A, Agarwal R, Joy C, et al. (2009). Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69, 4116-4124.
44. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, He X, and Perou CM (2010). Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12, R68.
45. DiSaia PJ, Sinkovics JG, Rutledge FN, and Smith JP (1972). Cell-mediated immunity to human malignant cells. A brief review and further studies with two gynecologic tumors. Am J Obstet Gynecol 114, 979-989.
46. Selby PJ, Thomas JM, Monaghan P, Sloane J, and Peckham MJ (1980). Human tumour xenografts established and serially transplanted in mice immunologically deprived by thymectomy, cytosine arabinoside and whole-body irradiation. Br J Cancer 41, 52-61.
47. Yuan X, Lin X, Manorek G, Kanatani I, Cheung LH, Rosenblum MG, and Howell SB (2009). Recombinant CPE fused to tumor necrosis factor targets human ovarian cancer cells expressing the claudin-3 and claudin-4 receptors. Mol Cancer Ther 8, 1906-1915.
48. Holzer AK and Howell SB (2006). The internalization and degradation of human copper transporter 1 following cisplatin exposure. Cancer Res 66, 10944-10952.
49. Albini A (1998). Tumor and endothelial cell invasion of basement membranes. The matrigel chemoinvasion assay as a tool for dissecting molecular mechanisms. Pathol Oncol Res 4, 230-241.
50. Ikenouchi J, Matsuda M, Furuse M, and Tsukita S (2003). Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail. J Cell Sci 116, 1959-1967.
51. Mironchik Y, Winnard PT Jr, Vesuna F, Kato Y, Wildes F, Pathak AP, Kominsky S, Artemov D, Bhujwalla Z, Van Diest P, et al. (2005). Twist overexpression induces in vivo angiogenesis and correlates with chromosomal instability in breast cancer. Cancer Res 65, 10801-10809.
52. Batlle E, Sancho E, Franci C, Dominguez D, Monfar M, Baulida J, and Garcia De Herreros A (2000). The transcription factor snail is a repressor of E-cadherin gene expression in epithelial tumour cells. Nat Cell Biol 2, 84-89.
53. Cano A, Perez-Moreno MA, Rodrigo I, Locascio A, Blanco MJ, del Barrio MG, Portillo F, and Nieto MA (2000). The transcription factor snail controls epithelialmesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2, 76-83.
54. Foty RA and Steinberg MS (2004). Cadherin-mediated cell-cell adhesion and tissue segregation in relation to malignancy. Int J Dev Biol 48, 397-409.
55. Lal-Nag M and Morin PJ (2009). The claudins. Genome Biol 10, 235.
56. Bolos V, Peinado H, Perez-Moreno MA, Fraga MF, Esteller M, and Cano A (2003). The transcription factor Slug represses E-cadherin expression and induces epithelial to mesenchymal transitions: a comparison with Snail and E47 repressors. J Cell Sci 116, 499-511.
57. Qian X, Karpova T, Sheppard AM, McNally J, and Lowy DR (2004). E-cadherinmediated adhesion inhibits ligand-dependent activation of diverse receptor tyrosine kinases. EMBO J 23, 1739-1748.
58. Cheng TC, Manorek G, Samimi G, Lin X, Berry CC, and Howell SB (2006). Identification of genes whose expression is associated with cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 58, 384-395.
59. Agarwal R, D'Souza T, and Morin PJ (2005). Claudin-3 and claudin-4 expression in ovarian epithelial cells enhances invasion and is associated with increased matrix metalloproteinase-2 activity. Cancer Res 65, 7378-7385.
60. Boylan KL, Misemer B, Derycke MS, Andersen JD, Harrington KM, Kalloger SE, Gilks CB, Pambuccian SE, and Skubitz AP (2011). Claudin 4 is differentially expressed between ovarian cancer subtypes and plays a role in spheroid formation. Int J Mol Sci 12, 1334-1358.